Journal: Cancer Immunology, Immunotherapy : CII
Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies
doi: 10.1007/s00262-026-04349-4
Figure Lengend Snippet: Generating a humanized stroma PDX (HS-PDX). A Tumor growth curves (i–iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC (combination iHUVEC/iHDMEC or EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). Tumor volumes in A (iv) are normalized TC + CA-MSC alone at 100%. B Representative IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) was used to label cell nuclei. C IF evaluation of a tumor-specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). D RNA-Seq-based relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. E Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration ( n = 4–7/treatment group). Tumor volumes are internally normalized to the initial measurement for each tumor (~ 100 mm 3 ). Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1. The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars in B and C are 20 µm
Article Snippet: RNA-seq data analyses were performed by Novogene and Dr. Hui Shen’s research group.
Techniques: Marker, RNA Sequencing, Expressing, Derivative Assay